4553.T
TOWA PHARMACEUTICAL CO.,LTD.
プライム · 医薬品 · 医薬品 · JP
JPY 3,650.00
+0.27%Aug 26, 2026, 05:24 UTC
Towa Pharmaceutical announced it received additional regulatory approval for its lenalidomide capsules 2.5mg/5mg 'TOWA', expanding the indications to include relapsed or refractory follicular lymphoma and marginal zone lymphoma, along with corresponding dosage and administration.
Source:Aug 18, 2026, 04:06 UTC
Towa Pharmaceutical announced on August 17 that it obtained manufacturing and marketing approval for 18 generic drug products across 7 ingredients, including first-time approvals for 4 ingredients such as guanfacine extended-release tablets for ADHD and linagliptin tablets for type 2 diabetes.
Source: